Owing to its crucial role in cancer progression, a range of EGFR-targeted therapies have been developed, including humanized monoclonal antibodies that bind to its extracellular domain and selective small-molecule inhibitors that block its tyrosine kinase domain. This evidence concerns the gene EGFR and cancer.